HighTower Advisors
AUPH icon

HighTower Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

HighTower Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,000
Closed -$1K – 2229
2017
Q2 		$1K Buy
+15,000
New +$101K ﹤0.01% 2186

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's AUPH Position: Q2 2026 in Review

HighTower Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 2.4% in Q2 2026, selling an estimated $8.74K and leaving 22,369 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

HighTower Advisors first reported a position in AUPH in Q2 2017 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • HighTower Advisors held 22,369 shares of Aurinia Pharmaceuticals worth $380K as of Q2 2026.
  • HighTower Advisors sold 547 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $8.74K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2994 holding.
  • HighTower Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.